Fractyl Health's Revita Retains Up to 84% of Weight Loss One Year After Stopping GLP-1s
GUTS has more than doubled off its 52-week low of $0.377.
Summary
In a randomized, sham-controlled study, Fractyl Health's Revita procedure retained up to 84% of GLP-1-induced weight loss one year after drug discontinuation, with no device-related serious adverse events. Topline pivotal data are expected in early Q4 2026.
Key Events · Product Development and Regulatory · GUTS
-
Revita Retains Up to 84% Weight Loss at One Year
In the REMAIN-1 Midpoint Cohort, a single Revita procedure retained 84% of GLP-1-induced weight loss in the optimized population (complete ablation plus at least 17.5% run-in weight loss) versus 46% with sham, translating to a greater than 70% reduction in weight regain.
-
Clean Safety Profile Supports Outpatient Use
Through 12 months, no device- or procedure-related serious adverse events occurred. Treatment-emergent adverse event rates were comparable between Revita (24%) and sham (25%), and all related events were mild and transient.
-
Pivotal Data Readout and FDA Submission on Deck
Topline six-month randomized data from the fully enrolled REMAIN-1 Pivotal Cohort are expected in early Q4 2026, with a potential FDA De Novo marketing application submission in late Q4 2026.
-
Clinical Validation Against Going-Concern Backdrop
The positive data arrive two months after Fractyl disclosed a going-concern warning and terminated its ATM offering, making this clinical milestone critical for the company's financing outlook and Nasdaq listing.
Analysis · GUTS · Industrial Applications And Services
Fractyl Health reported positive one-year data from its REMAIN-1 Midpoint Cohort, showing that a single Revita procedure can durably maintain weight loss after GLP-1 discontinuation. In the optimized population, the treatment retained 84% of on-drug weight loss versus 46% with sham, alongside a clean safety profile. These results materially de-risk the pivotal program and strengthen the case for a potential FDA De Novo submission in late 2026. The data arrive against a backdrop of a going-concern warning and terminated ATM, making this clinical validation critical for the company's survival and ability to raise capital on better terms.
At the time of this filing, GUTS was trading at $0.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $126.9M. The 52-week trading range was $0.38 to $2.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.